Title: Clinical Application and Market Overview of Tolterodine

First paragraph (overview):Tolterodine is a selective M receptor antagonist mainly used for the treatment ofOveractive bladder (OAB), improve symptoms such as frequent urination and urgency by inhibiting the contraction of bladder smooth muscle. This article will start from four aspects: pharmacological mechanism, clinical efficacy, market products and precautions for use, focusing on analyzing its core indications and safety.

Second paragraph (pharmacology and indications):Tolterodine significantly reduces detrusor overactivity by blocking bladder M3 receptors. Clinical studies have shown that it can reduceThe frequency of urination per day reaches 30%, especially suitable for patients with non-neurogenic OAB. It should be noted that it is contraindicated in patients with glaucoma or myasthenia gravis. Common side effects are dry mouth and constipation.

Paragraph 3 (clinical data):A controlled trial involving 1,200 patients showed that after 12 weeks of treatment with tolterodine (2 mg twice daily),The incidence of urinary urgency is reduced by 42%, the efficacy is better than that of the placebo group (p<0.01). However, elderly patients need to adjust the dose to avoid effects on cognitive function.

Paragraph 4 (Market Products):Major domestic marketed products include AstraZeneca’s"appropriate"(Detrol) and generic drugs, the price range is 50-200 yuan/box (14 tablets). Here is a comparison of major manufacturers:

Fifth paragraph (summary):Tolterodine is a first-line drug for OAB, and the key is to balance efficacy and safety. Patients need to follow medical advice to assess individual risks, and at the same time pay attention to the cost-effective advantages of domestic generic drugs. Sustained-release dosage forms may further improve medication compliance in the future.

Quote sources:
1. Chinese Journal of Urology "Guidelines for Diagnosis and Treatment of Overactive Bladder (2022 Edition)"
2. AstraZeneca drug instructions (approval date: 2021-03)
3. National Food and Drug Administration Generic Drug Reference Preparation Catalog (5th batch in 2023)